Status:
COMPLETED
A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients
Lead Sponsor:
McMaster University
Collaborating Sponsors:
Merck Frosst Canada Ltd.
Conditions:
Hip Fracture
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
The purpose of the study is to determine the best dose of Vitamin D to give to hip fracture patients to achieve the optimal therapeutic level.
Detailed Description
Low Vitamin D levels can cause faster bone loss and increase the risk of having a fracture. Patients who experience a hip fracture have low levels of Vitamin D. It is not clear how much Vitamin D must...
Eligibility Criteria
Inclusion
- Fragility hip fracture patient
- Previous Vitamin D supplementation is okay.
Exclusion
- Patients with pathological fracture secondary to malignancy or intrinsic bone disease (eg. Paget's disease)
- Cancer in the past 10 years likely to metastasize to bone
- Renal insufficiency (creatinine \<30 mls/min)
- Hypercalcemia (primary hyperparathyroidism; granulomatous diseases; drug-induced such as lithium, thiazides), hypocalcemia, hypercalciuria, fracture or stroke within the last 3 months
- Hormone replacement therapy, calcitonin, fluoride, or bisphosphonates during the previous 24 months
- Pre-existing bone abnormality
- Renal stones in past 10 years
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00424619
Start Date
October 1 2007
End Date
July 1 2009
Last Update
July 16 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.